The loan will provide direct equity-type financing supported by the Invest EU mandate to finance RD&I activities of an innovative Danish biopharmaceutical company for the development of its diversified portfolio of novel preclinical and clinical-stage peptide-based product therapeutics for metabolic (obesity, diabetes), gastrointestinal and rare diseases.
| InvestEU operation amount | EUR 90 million |
| Sector | Professionnal, scientific and technical activities + Manufacturing |
| Subsector | |
| Policy window | Research, innovation and digitisation (RIDW) |
| Approval by the Investment Committee | 12 December 2023 |
Links and documents
Conclusions - Project Hive-DK
Scoreboard - Project Hive-DK
Disclaimer: The Commission gives no warranty and makes no representation, whether expressed or implied, that the information is error free. The information is provided without any guarantees, conditions, or warranties as to its accuracy. This portal is made available for information purposes only.
- Reference
- INVEU-ICR-0107-2023
- Project locations
- Denmark
- Policy window
- Research, innovation and digitisation (RIDW)
- Eligible areas
- Research, development and innovation
- Implementing partner
- EIB